Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection | Zendy

Alan Noel | Zendy; Karen E. Bowker | Zendy; Marie Attwood | Zendy; Alasdair MacGowan | Zendy

Open Access

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection

Author(s) -

Alan Noel,

Karen E. Bowker,

Marie Attwood,

Alasdair MacGowan

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky225

Subject(s) - amikacin , meropenem , tazobactam , klebsiella pneumoniae , microbiology and biotechnology , population , medicine , antibiotics , biology , escherichia coli , antibiotic resistance , biochemistry , environmental health , imipenem , gene

To use a pre-clinical infection model to assess the antibacterial effect of human simulations of dosing with ceftolozane/tazobactam (with or without amikacin) or meropenem against Enterobacteriaceae and Pseudomonas aeruginosa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research